Florence

• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Ended
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended
  2023-506829-11-00 5 2019-05-29 Growth Hormone Deficiency in children
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended
  2023-508655-39-00 7 2019-02-13 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
• A study of full treatment-free remission in patients with chronic myeloid leukemia Ended
  2024-516122-66-00 4 2019-01-18 Chronic myeloid leukemia
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 4 2018-09-03 Mantle Cell Lymphoma
• A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advat … Ended
  2023-509769-18-00 5 2017-03-15 Hereditary severe von Willebrand Disease in children
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended
  2022-500302-18-00 4 Epilepsy
• Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended
  2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab … Ended
  2022-502335-19-00 5 Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hem
• Study of Obeldesivir in Children and Adolescents With COVID-19 Ended
  2023-503282-27-00 10 COVID-19
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS … Ended
  2024-512804-20-00 5 Metastatic Colorectal Cancer
• AUSTRAL trial: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in st … Ended
  2024-515942-18-01 4 Stage III NSCLC patients with loco-regional relapse > 12 months from t
• A Phase II, open label, single arm, multicentre study on THOracic Radiotherapy in Extensive Stage SCLC patients submitted to first line CHT- … Ended
  2024-517445-13-00 4 Extended stage small cell lung cancer patients confirmed histologicall

Showing 745–768 of 768 trials